A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer by Justin M Balko & Esther P Black
BioMed CentralBMC Cancer
ssOpen AcceResearch article
A gene expression predictor of response to EGFR-targeted therapy 
stratifies progression-free survival to cetuximab in KRAS wild-type 
metastatic colorectal cancer
Justin M Balko and Esther P Black*
Address: Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, USA
Email: Justin M Balko - jmbalk2@email.uky.edu; Esther P Black* - Penni.Black@uky.edu
* Corresponding author    
Abstract
Background: The anti-EGFR monoclonal antibody cetuximab is used in metastatic colorectal
cancer (CRC), and predicting responsive patients garners great interest, due to the high cost of
therapy. Mutations in the KRAS gene occur in ~40% of CRC and are a negative predictor of
response to cetuximab. However, many KRAS-wildtype patients do not benefit from cetuximab.
We previously published a gene expression predictor of sensitivity to erlotinib, an EGFR inhibitor.
The purpose of this study was to determine if this predictor could identify KRAS-wildtype CRC
patients who will benefit from cetuximab therapy.
Methods: Microarray data from 80 metastatic CRC patients subsequently treated with cetuximab
were extracted from the study by Khambata-Ford et al. The study included KRAS status, response,
and PFS for each patient. The gene expression data were scaled and analyzed using our predictive
model. An improved predictive model of response was identified by removing features in the 180-
gene predictor that introduced noise.
Results: Forty-three of eighty patients were identified as harboring wildtype-KRAS. When the
model was applied to these patients, the predicted-sensitive group had significantly longer PFS than
the predicted-resistant group (median 88 days vs. 56 days; mean 117 days vs. 63 days, respectively,
p = 0.008). Kaplan-Meier curves were also significantly improved in the predicted-sensitive group
(p = 0.0059, HR = 0.4109. The model was simplified to 26 of the original 180 genes and this further
improved stratification of PFS (median 147 days vs. 56.5 days in the predicted sensitive and resistant
groups, respectively, p < 0.0001). However, the simplified model will require further external
validation, as features were selected based on their correlation to PFS in this dataset.
Conclusion: Our model of sensitivity to EGFR inhibition stratified PFS following cetuximab in
KRAS-wildtype CRC patients. This study represents the first true external validation of a molecular
predictor of response to cetuximab in KRAS-WT metastatic CRC. Our model may hold clinical
utility for identifying patients responsive to cetuximab and may therefore minimize toxicity and cost
while maximizing benefit.
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A wealth of clinical data has confirmed the role of using
KRAS mutational status to stratify advanced-stage colorec-
tal cancer (CRC) patients to receive anti-EGFR mono-
clonal antibody (mAB) therapy [1-7]. Activating KRAS
mutations are strong independent negative predictors of
response to such treatment and mutational testing has
been included in colorectal cancer practice guidelines.
Interestingly, KRAS mutations may also predict lack of
response to EGFR tyrosine kinase inhibitors (TKI) in lung
cancer, suggesting a common mechanism of resistance to
anti-EGFR therapies in these two tumor types [8-10].
Importantly, a large percent of lung cancer and CRC
patients harboring wildtype KRAS, do not realize benefit
from EGFR-targeted agents [1,3,5,7]. Therefore, addi-
tional methods of patient stratification are required to
improve the tailoring of EGFR-targeted therapy in these
diseases.
We have previously published a gene expression predictor
of response (GEPR) to erlotinib in lung cancer [11]. The
180-gene model was built on Affymetrix microarray data
and genes were selected and weighted based on the
expression data from a series of lung cancer cell lines with
known sensitivities to erlotinib. The model was externally
validated using additional lung cancer cell lines as well as
in human tumors (reference 11 and unpublished data).
Given the correlation between KRAS mutational status
and response to both EGFR-mAB and EGFR-TKI in lung
and colorectal tumors, we hypothesized that our previ-
ously published GEPR is capable of predicting response to
cetuximab in metastatic CRC.
Khambata-Ford and colleagues conducted a study with
over 100 CRC patients wherein metastatic sites were biop-
sied, mutational status of KRAS was determined, and gene
expression data was generated [12]. Following the biopsy,
patients were treated with cetuximab as monotherapy and
response and progression-free survival were recorded. The
purpose of that study was to identify predictive biomark-
ers for response to cetuximab.
The publication of these data presented an excellent
opportunity to test our hypothesis that the 180-gene
GEPR to erlotinib generated in lung adenocarcinoma cell
lines was portable to KRAS-wildtype CRC in predicting
response to cetuximab. Since the data published by
Khambata-Ford and colleagues was not available until
almost a year following the publication of our predictive
model, the data could be utilized to perform a true exter-
nal validation, essentially equivalent to an independent
prospective study due to the sequence and timing of the
involved publications.
The primary endpoint of our study was to test the ability
of our predictive algorithm to segregate cetuximab
responders from non-responders in the KRAS-wildtype
population included in the Khambata-Ford study. We
found that our GEPR of erlotinib response was strongly
predictive of cetuximab response with no gene-weighting
adjustment or additional gene selection. However, reduc-
ing the signature to 26 of 180 genes based on the correla-
tion of those genes to survival in the Khambata-Ford
dataset significantly improved the predictive accuracy and
Kaplan Meier curve separation. Importantly, the refined
signature retained the original weights from the NSCLC
model-training data, reducing the likelihood of over-fit-
ting.
The most significant finding of this study was that the
GEPR was capable of predicting progression-free survival
in another tumor type than that on which the model was
built, and with another EGFR-targeted agent. Similarly,
other groups have previously reported portability of gene
expression signatures [13,14]. We believe that this model
could be highly useful in predicting response to cetuxi-
mab in CRC in patients with KRAS-wildtype tumors. Fur-
thermore, additional studies to validate the predictive
capacity of the model in other appropriate tumor types are
underway.
Methods
Gene expression predictor of response to EGFR-targeted 
agents
The GEPR to EGFR-targeted agents was built using lung
cancer cell lines and sensitivity data to the EGFR-tyrosine
kinase inhibitor erlotinib. Briefly, the GEPR uses the
MAS5-normalized Affymetrix signal intensity values from
180 genes which are represented on the Affymetrix U133
platform. These features are used to perform diagonal lin-
ear discriminant analysis (DLDA) in order to make a
group selection of 'sensitive' or 'resistant' based on the
similarity of the test sample to the 'sensitive' and 'resistant'
training (model) data. The details regarding gene selec-
tion, weighting, and methods required to perform the
analysis are reported elsewhere [11]. All predictive analy-
ses for this study were carried out in R statistical language.
Data analysis and prediction
The data from Khambata-Ford et al were extracted in series
matrix format from Gene Expression Omnibus (GEO)
record GSE5851[12]. The data from that study were scaled
by the authors to mean intensity of 1500. Therefore, the
data matrix was multiplied by a factor of 0.333 in order to
reflect the mean intensity value of the data used to gener-
ate our GEPR (500). This direct linear relationship was
confirmed by scaling experimental data to both values
using Expression Console (Affymetrix, Santa Clara, CA)
and observing the ratios on a probe by probe basis. A ratio
of precisely 0.333 was observed for all probesets, confirm-
ing the validity of this approach to data handling (data
not shown). The clinical response data and KRAS statusPage 2 of 10
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Khambata-Ford et al [12].
No changes were made to the predictive algorithm. The
test matrix was truncated to the 180 predictive genes
included in the original model and imported into R for
DLDA. Details regarding the analysis and model have
been previously reported [11]. Data from the Khambata-
Ford study were separated into three datasets: KRAS-
wildtype, KRAS-mutant, or all patients combined. After
sensitivity prediction on each of the datasets, the results
were imported into Excel (Microsoft, Redmond, WA) and
cross referenced with response and progression free sur-
vival (PFS).
Model refinement
The 180 signature genes were filtered for their correlation
to survival in the Khambata-Ford dataset. Specifically,
ratios of gene expression values were calculated for the
best (> 150 days PFS) relative to the worst-performing
patients (< 50 days PFS). These cutoffs were selected based
on the finding that they produced similarly sized cohorts
of patients (approximately 1/3 of the dataset). These
cohorts were used only to determine directionality of the
genes (i.e. up in better-responding or down in better-
responding). Similar ratios were calculated for each gene
for the sensitive relative to resistant training (NSCLC)
dataset. Next, genes which did not display directional con-
cordance were filtered (i.e. genes with calculated ratios in
both datasets > 1 or calculated ratios in both datasets < 1
were retained). This filtering step was performed because
genes which show an association with response in the test
dataset, but in the opposite direction, could confound the
predictive model and are therefore not likely to improve
the accuracy of the test. The remaining genes were further
filtered based on their absolute correlation to PFS in the
Khamabata-Ford dataset. Twenty-six of the original 180
genes were identified that had absolute Pearson's correla-
tion coefficients of ≥ 0.2 and had directional concordance
with the NSCLC model-training data. These 26 features
were retained in the 'refined' model. This procedure was
utilized only as a gene-filtering step, as the original
weighting for these genes in the predictive algorithm was
retained.
Statistical analysis
All statistical analyses were performed using Prism
(Graphpad, La Jolla, CA) and checked using JMP (SAS,
Cary, NC). For comparisons of median progression free
survival, the 2-tailed Mann-Whitney U test was performed
between groups predicted to be sensitive and those pre-
dicted to be resistant. Kaplan-Meier survival curves were
generated based on the PFS data reported by Khambata-
Ford et al and analyzed by the log-rank statistic [12].
These analyses were performed on only the KRAS-
wildtype patient data first, and then repeated on all
patient data as well as the KRAS-mutant population inde-
pendently for comparison.
Results
The gene expression predictor of response to erlotinib also 
predicts response and disease control to cetuximab in 
mCRC
The 180-gene GEPR provides a model which weights
genes based on the expression values determined from a
panel of NSCLC cell lines stratified by their sensitivity to
the EGFR inhibitor erlotinib. This model was applied to
the metastatic CRC data from Khambata-Ford et al. The
microarray data from 80 of the 110 patients enrolled in
that study were available for analysis. Of these, 43
(53.8%) were confirmed wildtype and 27 (33.8%) had
confirmed KRAS mutations. The KRAS status of the
remaining 10 (12.5%) patients was not reported.
Since KRAS status is used to determine the CRC patients
who should receive cetuximab, the primary endpoint of
our study was to determine if the GEPR could correctly
stratify KRAS-wildtype patients according to response/dis-
ease control. Indeed, when the prediction results were
matched to response as reported by Khambata et al, our
predictive model correctly captured 5/5 partial and com-
plete KRAS-wildtype responders (Figure 1A). Also, 12/15
patients who demonstrated stable disease were classified
as 'sensitive' by the GEPR. Thus, the majority (17/20,
85%) of patients demonstrating overall disease control
(SD+PR+CR) were captured in the 'sensitive' group.
As a secondary endpoint, we wished to determine if the
predictive signature was an independent predictor of
response and/or disease control to cetuximab. To assess
this, we analyzed all of the patient data, irrespective of
KRAS status. Interestingly, when all 80 patients were con-
sidered, the GEPR retained predictive capacity (Figure 1B),
although the most significant enrichment (Fisher's exact
test, p = 0.001) of responding and SD patients were
observed when the GEPR was applied only to KRAS-
wildtype patients. No PRs or CRs were noted in KRAS-
mutant patients, consistent with previous findings
[2,5,7,12]. Nonetheless, 2/2 KRAS-mutant patients dem-
onstrating stable disease to cetuximab were captured in
the sensitive group (Figure 1C). Calculated parameters
(specificity, sensitivity, negative predictive value, and pos-
itive predictive value) for the ability of the model to pre-
dict disease control are given in Table 1. Negative
predictive values were consistently higher than positive
predictive values, regardless of the cohort tested. This indi-
cates that a high number of false positives are associated
with this 180-gene model. However, in the absence of a
genomic data to predict response, most wildtype KRAS
mCRC patients could be considered candidates for cetux-Page 3 of 10
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cerning. The high NPV of the test suggests that the test
could be accurately used to identify patients who will not
benefit from anti-EGFR treatment (negative screen).
The gene expression predictor of response to erlotinib 
stratifies cetuximab-treated mCRC patients based on 
progression-free survival
We next determined whether KRAS-wildtype patients
identified by the model as 'sensitive' would exhibit true
clinical benefit when compared to those classified as
'resistant'. Scatter-plots and Kaplan-Meier survival curves
of the progression-free survival (PFS) were generated for
both predicted groups in KRAS-wildtype patients (Figure
2). PFS was significantly greater in the KRAS-wildtype
patients who predicted as 'sensitive' (median PFS: 88
days, mean PFS: 117 days, 95% CI: 90.8 – 143.8 days)
compared to those that predicted as 'resistant' (median
PFS: 56 days, mean PFS: 63 days, 95% CI: 29.9 – 96.9
days) (Figure 2A, left). The difference in PFS was statisti-
Group classifications coupled with response data based on the 180-gene GEPR to EGFR-targeted therapyFigure 1
Group classifications coupled with response data based on the 180-gene GEPR to EGFR-targeted therapy. 
Patient populations from Khambata-Ford et al were classified using our predictive model. Percentage of patients exhibiting each 
annotated radiographic responses (CR/PR – complete responses and partial responses, SD – stable disease, PD – progressive 
disease, NA – not available/not reported) are classified as 'sensitive' or 'resistant' groups. A: KRAS-wildtype patients (43 sub-
jects); B: all patients (80 subjects); and C: KRAS-mutant patients (27 subjects).
Table 1: Calculated parameters for the ability of the GEPR to 
predict disease control
Parameter KRAS-wildtype All patients KRAS-mutant
Specificity 0.32 0.4 0.5
Sensitivity 0.85 0.8 1
PPV 0.57 0.43 0.18
NPV 0.66 0.77 1
NPV: negative predictive value; PPV positive predictive valuePage 4 of 10
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The 180-gene GEPR to EGFR-targeted therapy stratifies a patient population demonstrating longer progression-free survival in metastatic CRC patients treated wi h cetuximabFigure 2
The 180-gene GEPR to EGFR-targeted therapy stratifies a patient population demonstrating longer progres-
sion-free survival in metastatic CRC patients treated with cetuximab. The data from Khambata-Ford et al were clas-
sified using our predictive model and matched to PFS. The scatter plots (left) depict the individual data points and median PFS 
for each group. The Kaplan-Meier survival curves (right) depict PFS between the 'sensitive' (green) and 'resistant' (red) groups. 
A: KRAS-wildtype patients; B: all patients; and C: KRAS-mutant patients.
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Mann-Whitney U test). The difference in the Kaplan-
Meier survival curves was highly statistically significant
when analyzed by the log-rank statistic for the KRAS-
wildtype group (Figure 2A, right).
When the entire cohort was included in the analysis,
regardless of KRAS status, the difference remained statisti-
cally significant (p = 0.0254, two-tailed Mann-Whitney U
test) (Figure 2B, left). However, the differences in median
and mean PFS were smaller (median PFS: 60 vs. 57.5 days
and mean PFS: 104.7 vs. 60.5 days in 'sensitive' and 'resist-
ant' subgroups, respectively). The difference in the Kap-
lan-Meier survival curves retained significance in the
entire cohort, supporting the secondary hypothesis that
the GEPR was an independent predictor of cetuximab
benefit (Figure 2B, right). The PFS in the KRAS-mutant
subgroup, when analyzed independently, was not statisti-
cally different between 'sensitive' and 'resistant' subgroups
(Figure 2C).
Refinement of the GEPR improves stratification of survival 
in KRAS-WT patients
The 180-gene GEPR was effective in stratifying PFS in
KRAS-WT patients. However, we wished to determine if
the model features, which had been pre-defined, could be
reduced to a suitable number for an alternate analytical
method, such as qRT-PCR. Furthermore, data reduction
could eliminate noisy genes, or those from the original
model that are predictive in NSCLC but not predictive in
colorectal cancer. To test this hypothesis, we filtered the
180 genes based on their directional concordance
between the training data (NSCLC cell lines) and the CRC
data. Genes that were more highly expressed in the sensi-
tive NSCLC cell lines relative to the resistant lines while
also being more highly expressed in CRC patients with a
PFS of > 150 days were retained. Similarly, genes that were
more highly expressed in the resistant NSCLC cell lines
relative to the sensitive cell lines while also being more
highly expressed in CRC patients with a PFS of < 50 days
were retained. Finally, correlations of the remaining genes
with PFS were calculated and those with an absolute value
of correlation ≥ 0.2 were retained while those that were <
0.2 were filtered. A correlation cutoff of |0.2| returned a
suitable number of genes and vastly improved differences
in median survival between the two groups. A cutoff of
|0.3| yielded only 8 genes, which we speculated may have
a decreased likelihood of capturing tumor heterogeneity.
Indeed, this signature did not effectively predict PFS in the
dataset (data not shown). A cutoff of |0.1| yielded 75
genes, which we perceived to be a suboptimal data reduc-
tion step. This 75 gene signature improved predictions,
but not as significantly as a cutoff of r = |0.2| (data not
shown). Thus, twenty-six genes comprised the 'refined'
model (Table 2). The weights for the 26 genes were
retained from the original GEPR, to minimize over-fitting
the model. A heatmap of the signal intensities of the 26
retained genes demonstrated a pattern of deregulation
coincident with PFS (Figure 3A).
When the refined model was applied to the KRAS-WT
CRC data, the resulting difference in PFS between the pre-
dicted-sensitive and predicted-resistant group was highly
significant (median 147 days vs. 56.5 days in the pre-
dicted sensitive and resistant groups, respectively, p <
0.0001) (Figure 3B and 3C). Kaplan-Meier curves demon-
strated significant separation as well. Parameters (sensitiv-
ity, specificity, NPV and PPV) for the refined model to
predict disease control (SD/PR/CR) are presented in Table
3. Parameters were improved for the 26-gene model over
the 180-gene model for all cohorts tested. Thus, as we
have demonstrated, the utility of the model is greatly
enhanced by enriching for genes which correlate with PFS.
Discussion
The anti-EGFR monoclonal antibodies cetuximab and
panitumumab are frequently used in metastatic CRC and
improve overall survival when used in unselected popula-
tions [15-19]. However, a number of independent studies
have elucidated the correlation of activating mutations in
KRAS with lack of response to EGFR-targeted agents, and
patient stratification based on KRAS status should
improve overall survival through enrichment of respond-
ing patients [1-6]. However, a significant number of
KRAS-wildtype patients do not benefit from treatment,
and therefore additional methods to enrich the treated
population for responders are needed to reduce unneces-
sary toxicity and cost while maximizing therapeutic bene-
fit from these agents. Indeed, Karapetis and colleagues
reached the conclusion that additional biomarker
approaches are needed to identify KRAS-wildtype patients
who will receive benefit from cetuximab in one of the
largest analyses to date of the association of KRAS status
with clinical outcome to cetuximab in CRC [7].
In this study, we utilized a GEPR for erlotinib, an EGFR-
TKI, which was generated in lung cancer cell lines, to test
its predictive capacity in KRAS-wildtype mCRC patients
treated with the anti-EGFR mAB cetuximab. It is impor-
tant to note that the GEPR generated in lung cancer cell
lines and was not dependent on either KRAS or EGFR
mutation status. Further, the genes included in the signa-
ture demonstrate biological association with pathways
downstream of EGFR, including both the PI3K/AKT and
MAPK pathways [11].
Application of our model to the CRC dataset represents a
true external validation of the GEPR since the validation
set was not available until well after the reporting of our
GEPR model. The availability of this dataset allowed us toPage 6 of 10
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alternate EGFR-targeted agents, employ the use of KRAS
status to enrich the predictive power, and function across
tumor types (CRC versus non-small cell lung) [11,12].
Surprisingly, the unaltered 180-gene model had a high
capacity to stratify KRAS-wildtype CRC patients who dem-
onstrated disease control or response to cetuximab treat-
ment. The data were furthered by the significant
separation of the survival curves of the predicted 'sensi-
tive' group versus the predicted 'resistant' group.
Importantly, these results were achieved even though the
genes that comprised the model were selected and
weighted based on the genomic expression in lung cancer
cell lines. Unlike the data reported by Khambata-Ford and
colleagues, neither amphiregulin (AREG) nor epiregulin
(EREG) are included in our GEPR. Further, RNA isolation
from biopsy of metastatic CRC of unknown tumor cell
content and subsequent microarray hybridizations were
all performed at a different facility than our own.
In the original report, Khambata-Ford and colleagues
used AREG and EREG expression to stratify KRAS-
wildtype patients, and found a significant improvement
in PFS in the 'high' ligand expressers group (EREG: P =
.0002, hazard ratio [HR] = 0.47, and median PFS, 103.5 v
57 days, respectively; AREG: P < .0001, HR = 0.44, and
median PFS, 115.5 v 57 days, respectively)[12]. The differ-
ences in median survival reported in that study are greater
than those identified in our study using the original 180-
gene model. It is not surprising that the authors were able
to demonstrate separation of the survival curves between
high ligand expressers and low ligand expressers because
AREG and EREG were chosen as biomarkers post-hoc.
AREG and EREG were selected from over 600 genes after
the response and progression free survival in the study
population was already determined. Optimal cutoff
expression levels were obtained from a receiver-operator
characteristic (ROC) curve, and changes in median PFS
were then calculated on the same data used to generate
these variables. It has yet to be shown whether AREG and
EREG hold any external validity as predictors of cetuxi-
mab response. In contrast, our predictive model was gen-
erated prior to the reporting of the Khambata-Ford data
and using these data, provides true external validity of our
model. The improvement in progression-free survival that
we identified in the predicted 'sensitive' KRAS-wildtype
mCRC patients was approximately 1 month. Given that
cetuximab yields an overall benefit in PFS of 1.5 months
as monotherapy in CRC as well as the high cost of treat-
ment, these findings should be considered clinically
important [20].
In light of the cost associated with microarray analysis, we
went on to attempt to reduce the number of predictive
genes necessary to achieve both response prediction and
Table 2: Features of the 26-gene refined model
Gene Description Affymetrix Probe ID
DDR1 discoidin domain receptor tyrosine kinase 1 1007_s_at
PRDX4 peroxiredoxin 4 201923_at
RYK RYK receptor-like tyrosine kinase 202853_s_at
HMOX1 heme oxygenase (decycling) 1 203665_at
GNB5 guanine nucleotide binding protein (G protein), beta 5 204000_at
PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 204369_at
ELMO1 engulfment and cell motility 1 204513_s_at
GPSM2 G-protein signaling modulator 2 (AGS3-like, C. elegans) 205240_at
PTK7 PTK7 protein tyrosine kinase 7 207011_s_at
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 207643_s_at
ECOP EGFR-coamplified and overexpressed protein 208091_s_at
RAC1 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) 208641_s_at
RGL2 ral guanine nucleotide dissociation stimulator-like 2 209110_s_at
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b 209295_at
PRKCI protein kinase C, iota 209678_s_at
MAPK13 mitogen-activated protein kinase 13 210058_at
VEGFA vascular endothelial growth factor A 210512_s_at
RHOB ras homolog gene family, member B 212099_at
NUDT4 nudix (nucleoside diphosphate linked moiety X)-type motif 4 212181_s_at
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 212255_s_at
GNAS GNAS complex locus 212273_x_at
CAMK2G calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma 212757_s_at
ITGA6 integrin, alpha 6 215177_s_at
P2RY5 purinergic receptor P2Y, G-protein coupled, 5 218589_at
PRKD2 protein kinase D2 38269_at
CC2D1A coiled-coil and C2 domain containing 1A 58994_atPage 7 of 10
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study. In so doing, we found that refining the GEPR, using
a subset of 26 of the original 180 genes, greatly improved
the sensitivity and specificity of the GEPR. Furthermore,
using the refined 26-gene GEPR significantly improved
the difference in median PFS between the predicted-sensi-
tive and predicted-resistant groups and resulted in
improved predictions compared with those reported by
Khambata-Ford et al. Distinct differences in the gene
expression patterns are observed in the gene expression
values (color scheme of the heat map in Figure 3) of the
26 feature signature, clearly identifying a trend which cor-
responds to PFS. However, the variability of these patterns
observed on a per gene basis highlights the necessity of
using multiple features to capture the heterogeneity of
tumors. As with the Khambata-Ford analysis, careful inter-
Model refinement to 26 features improves predictive accuracyFigure 3
Model refinement to 26 features improves predictive accuracy. A. Heatmap of signal intensities for the 26 genes in the 
refined model plotted by clinical sample. All clinical samples were included (KRAS WT, KRAS-mutant, and unconfirmed/NA) 
and are arranged according to PFS. Sixty and 120 day PFS are identified on the scale for approximate reference. KRAS-mutant 
samples (codon 12) are designated by red arrows. Genes which are more highly expressed in the 'sensitive' training data are 
marked with red on the probeset axis, while gene more highly expressed in the 'resistant' training data are marked in green. B. 
The confirmed KRAS-WT samples were plotted by predicted sensitivity. Closed circles and bars represent individual PFS and 
median PFS for the group, respectively. C. The Kaplan-Meier survival curve depicts PFS between the 'sensitive' (green) and 
'resistant' (red) groups. The reported p-value is for the log-rank statistic.Page 8 of 10
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is necessary. Because information from the validation set
was utilized in feature selection, over-fitting remains a
possibility. The refined GEPR reported here retains the
original weights of the 26 genes, reducing the chance of
over-fitting. Additional validation will test that hypothesis
and determine if the 26-gene GEPR can be used in a qRT-
PCR analysis rather than on an Affymetrix platform.
While the 180-gene GEPR was useful for stratifying KRAS-
wildtype patients, we also wished to determine whether
the GEPR could stratify patients independently of KRAS
status. Statistical significance was retained in both median
PFS and the log-rank analyses when patients were not
stratified based on KRAS status, suggesting that the signa-
ture is an independent predictor of benefit to cetuximab
therapy in mCRC. However, patients with KRAS-mutant
CRC tumors who predicted as 'sensitive' did not have
longer PFS than those who predicted as 'resistant',
although this could be due to the small sample size
included in this particular analysis. It is of note that one
patient with a KRAS-mutant tumor was reported by
Khambata et al to have had a PFS of > 1 year on cetuxi-
mab, although radiographic response in this patient was
not recorded. Our 180-gene GEPR classified this patient as
'sensitive', offering additional support of the independ-
ency of our test from KRAS mutational status. However, a
significant number of non-responding KRAS-mutant
patients were called 'sensitive' by the GEPR, contributing
to a poor positive predictive value in this group.
To further explore the relationship between the GEPR pre-
diction status and KRAS status, we performed a χ2 test. No
association with KRAS status was found in the prediction
outcomes for either the 26-gene (p = 0.2) or the 180-gene
signature (p = 0.3). Thus, our test appears to be independ-
ent of KRAS status. On a per gene basis, we also examined
whether any of the 180 genes were significantly different
between the KRAS-wildtype and KRAS-mutant cohorts. Of
the 180 genes, 32 were p < 0.05 according to a two tailed
t-test (although a Bonferroni correction yielded no signif-
icantly deregulated genes). However, only 3 of these genes
were included in the final 26 gene signature (ATP2C1,
P2RY5, and TNFRSF10B). Thus, this test offers an explana-
tion for why the 26-gene signature demonstrated
improved predictive accuracy over the 180-gene signature,
as the majority of genes associated with KRAS activation
appear to have been removed during gene list filtering.
Our GEPRs, 180- or 26-gene, may be best utilized in tan-
dem with KRAS-mutational testing. Importantly, our
methodology could easily be combined with KRAS muta-
tional testing through biopsy of metastatic sites and allot-
ment of tissue cores for both RNA and DNA purification.
The high sensitivity and negative predictive value of the
test suggests that use of the model could be implemented
to significantly enrich the responding patient population
while minimizing the number of potential-responders
(i.e. false negatives) who would be diverted from receiv-
ing cetuximab.
Conclusion
These data suggest that the 180-gene GEPR will be a valu-
able clinical tool in determining who should receive
cetuximab therapy in metastatic colorectal cancer, per-
haps best used in combination with KRAS status. More
studies will be necessary to determine whether the predic-
tive capacity of the model is retained in patients treated
with cetuximab plus chemotherapy or in patients treated
with panitumumab. Additional validation in NSCLC and
CRC, and potentially other epithelial tumor types, will
confirm the broader clinical utility of this predictive
model, as well as assess the true external validity of the
refined 26-gene model.
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